Answer
Venous thromboembolic events, including deep venous thrombosis and pulmonary embolism, including fatal events, have been reported with lazertinib in combination with amivantamab.
Sources for this answer
- Lazcluze 80 mg film-coated tabletsJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.4 Special warnings and precautions for use · Version 3Document updated
Sources checked